Astec Lifesciences' Q3 FY 2025-26 Quarterly Results
- 31 Jan 2026
Result Summary
- Astec Lifesciences Ltd reported a 67.7% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 31.1%.
- Its expenses for the quarter were up by 40.2% QoQ and 15.1% YoY.
- The net profit decreased 35.7% QoQ and decreased 61.1% YoY.
- The earnings per share (EPS) of Astec Lifesciences Ltd declined at 7.04 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 125.54 | 74.84 | 95.77 | 67.7% | 31.1% |
Total Expenses | 139.12 | 99.25 | 120.92 | 40.2% | 15.1% |
Profit Before Tax | -15.68 | -24.41 | -25.15 | -35.8% | -37.7% |
Tax | 0.01 | 0.01 | 15.22 | 0.0% | -99.9% |
Profit After Tax | -15.69 | -24.42 | -40.37 | -35.7% | -61.1% |
Earnings Per Share | -7.04 | -11.34 | -20.59 | -37.9% | -65.8% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Astec Lifesciences Ltd is a company that operates in the agricultural chemical sector. The company is primarily engaged in the manufacturing and sale of agrochemical products, which include fungicides, herbicides, insecticides, and intermediates. These products are critical in enhancing crop protection and agricultural productivity. Astec Lifesciences has been focusing on expanding its product portfolio and increasing its market presence in both domestic and international markets. The company aims to leverage its research and development capabilities to introduce innovative solutions in the agrochemical space. Specific recent developments regarding the company are not available at this time.
Revenue
In the third quarter of fiscal year 2026, Astec Lifesciences Ltd reported a total income of ₹125.54 crores. This represents a significant increase of 67.7% compared to the previous quarter's income of ₹74.84 crores. On a year-over-year basis, the total income increased by 31.1% from ₹95.77 crores in Q3FY25. These figures suggest a strong upward trend in revenue generation over both the quarterly and annual periods. The revenue growth indicates an increase in the company's operational scale and market demand for its products during this period.
Profitability
Astec Lifesciences reported a loss before tax of ₹15.68 crores in Q3FY26, which is an improvement from the loss of ₹24.41 crores in the previous quarter. Compared to the same quarter of the previous fiscal year, the loss before tax decreased by 37.7% from ₹25.15 crores. The profit after tax for Q3FY26 was a loss of ₹15.69 crores, which is an improvement compared to the loss of ₹24.42 crores in Q2FY26 and a significant improvement from the loss of ₹40.37 crores in Q3FY25. The earnings per share (EPS) also showed improvement, with a negative ₹7.04 in Q3FY26 compared to negative ₹11.34 in Q2FY26 and negative ₹20.59 in Q3FY25.
Operating Metrics
The company's total expenses for Q3FY26 were reported at ₹139.12 crores, marking a 40.2% increase from ₹99.25 crores in the previous quarter. Compared to the same quarter in the previous year, the total expenses increased by 15.1% from ₹120.92 crores. Despite the increase in expenses, the company managed to reduce its loss margins over both the quarter-on-quarter and year-on-year comparisons. The tax expenses remained minimal at ₹0.01 crores for both Q3FY26 and Q2FY26, while a significant tax expense of ₹15.22 crores was recorded in Q3FY25. This decrease in tax expense year-over-year contributed to the improvement in net loss figures.